NCT05009836进行中（未招募）3 期
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Hutchmed
- 入组人数
- 412
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
详细描述
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;
- •In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanced (stage ⅢB/ⅢC), metastatic or recurrent (stage IV) NSCLC who are not suitable for radical concurrent chemoradiotherapy;
- •Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression
- •Having measurable lesions (in accordance with RECIST 1.1 criteria);
- •ECOG Performance Status score 0 or 1, or Karnofsky score ≥80;
- •Survival is expected to exceed 12 weeks;
- •No any previous systematic antitumor therapy for advanced/metastatic disease;
- •adequate bone marrow reserve or organ function
- •Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 6 weeks after discontinuation of the study drug , and agree not to donate ova (oocytes) for reproductive purposes during this period;
- •Male patients whose sexual partners are women of childbearing potential must use condoms during sexual intercourse during the study and within 6 months after discontinuation of study drug
- •Being able to take or swallow the drug orally.
排除标准
- •Previous treatment with EGFR inhibitors or MET inhibitors;
- •Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years;
- •Antitumor therapy within 2 weeks prior to the start of study treatment, including hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for antitumor indication;
- •Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89) within 4 weeks prior to the start of study treatment or palliative local radiotherapy within one week prior to the start of study treatment, or the above adverse reactions of radiotherapy did not recover;
- •Having received a major surgery within 4 weeks prior to the start of study treatment or a minor surgery (except biopsy, and venous catheterization) within one week prior to the start of study treatment;
- •Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;
- •Having not been sufficiently recovered from the toxicity and/or complication resulting from any interventional measure prior to the start of treatment;
- •Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);
- •Active hepatitis B, or active hepatitis C;
- •Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;
- •Uncontrollable hypertension despite the use of drugs,
- •Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;
- •Patients whose known cancerous thrombus or deep vein thrombosis are stable for ≥2 weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues with similar efficacy can be enrolled;
- •Any important abnormality in rhythm
- •Presence of meningeal metastasis, spinal cord compression or active brain metastasis prior to the start of study treatment.
- •Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;
- •Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;
- •Having participated in other drug clinical trials and received the study drug within 3 weeks prior to the start of study treatment;
- •Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;
- •Previous history of interstitial lung diseases, drug-induced interstitial lung diseases, radiation pneumonitis requiring glucocorticoid therapy and any active interstitial lung diseases;
- •Pregnant and lactating women;
- •Any other disease, metabolic abnormality, physical examination abnormality or laboratory examination abnormality, certain disease or state, based on which there is a reason to suspect that the subject is not suitable for the study drug, or one condition that will affect intepretaton of the study results or put the subject at high risk.
- •History of cirrhosis of any etiology and clinical stage; or other severe liver disease or chronic disease with severe liver involvement.
研究组 & 干预措施
Savolitinib
Experimental
Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
干预措施: Savolitinib (Drug)
placebo
Placebo Comparator
Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
干预措施: Placebo (Drug)
结局指标
主要结局
PFS
时间窗: 17 months after the last patient enrolled
Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
次要结局
- Safety and tolerability(17 months after the last patient enrolled)
- The objective response rate of the tumor (ORR)(17 months after the last patient enrolled)
- The disease control rate (DCR)(17 months after the last patient enrolled)
- Duration of Response (DoR)(17 months after the last patient enrolled)
- Overall survival (OS)(17 months after the last patient enrolled)
- Time to Response (TTR)(17 months after the last patient enrolled)
- Development of diagnostic technology(17 months after the last patient enrolled)
- PFS(17 months after the last patient enrolled)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentCarcinomaNon-Small-Cell LungNCT05261399AstraZeneca341
进行中（未招募）
3 期
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCPapillary Renal Cell CarcinomaNCT05043090AstraZeneca148
进行中（未招募）
3 期
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNon-Small Cell Lung CancerNCT05120349AstraZeneca390
进行中（未招募）
2 期
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCNon-Small Cell Lung CancerNCT04606771AstraZeneca30
招募中
2 期
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialEGFR Activating MutationCell Cycle DeregulationEGFR-TKI Resistant MutationNon-small Cell Lung CancerNCT06363734Tianjin Medical University Cancer Institute and Hospital32